RARA and acute promyelocytic leukemia: None of the patients who died before day 42 of therapy had favorable genetics, excluding patients with APL (in 3 of 4 PML::RARA mutations were identified, in one no cytogenetic or molecular studies were performed, the diagnosis of APL was made on the basis of the morphology of leukemic blasts only).